Multiple immune and tumor cell surface receptors

The term Multiple immune and tumor cell surface receptors is a collective descriptor rather than a specific, individual therapeutic target. It encompasses a wide array of proteins found on the plasma membranes of leukocytes and malignant cells, including immune checkpoint receptors such as Programmed cell death protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), as well as tumor-associated antigens like HER2 and CD20. These receptors are central to the regulation of the immune system's ability to recognize and eliminate cancer cells (Pardoll, D. M., 2012, Nature Reviews Cancer). In clinical practice, therapies are designed to target specific members of this group to modulate immune signaling or induce direct tumor cell death (Mellman, I., et al., 2011, Nature). Because this entry represents a heterogeneous group of molecules with diverse structures and functions, it cannot be classified as a single canonical target for drug development. Instead, it serves as a broad classification for the various molecular interfaces involved in immuno-oncology research and therapeutic intervention.

Not applicable; this term refers to a broad category of proteins rather than a single molecular target.